Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23507763 | 0.88 | MAOB (1.00) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| SCHEMBL23507575 | 0.88 | MAOB (1.00) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| SCHEMBL5958538 | 0.88 | MAPT (0.78) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| SCHEMBL17430038 | 0.87 | MAPT (0.80) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| SCHEMBL23694179 | 0.86 | MAOB (0.77) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| SCHEMBL5960271 | 0.86 | MAOB (0.77) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| Thk-5351 SCHEMBL5958544 | 0.85 | MAPT (1.00) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| SCHEMBL5958403 | 0.85 | MAPT (1.00) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| Thk-5351 SCHEMBL16829186 | 0.85 | MAPT (1.00) | MAOBMAPTPDE3BPDE3AP2RY12 | |
| Thk-5351 SCHEMBL17430219 | 0.85 | MAPT (1.00) | MAOBMAPTPDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2634177-A1 | TAU IMAGING PROBE | Clino Ltd. (JP) | 2013-09-04 | — | — | EP | claimed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| WO-2017103257-A1 | MONOAMINE OXIDASE B BINDERS FOR USE IN THE TREATMENT AND THE DIAGNOSTIC OF ALZHEIMER DISEASE | CLINO LIMITED (JP) | 2017-06-22 | — | — | WO | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20160271278-A1 | TAU IMAGING PROBE | GE HEALTHCARE LTD (GB) | 2016-09-22 | — | — | US | disclosed |
| US-20160271278-A1 | TAU IMAGING PROBE | GE HEALTHCARE LTD (GB) | 2016-09-22 | — | — | US | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20130324523-A1 | TAU IMAGING PROBE | CLINO LTD. (JP) | 2013-12-05 | — | — | US | disclosed |
| EP-2634177-A1 | TAU IMAGING PROBE | Clino Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634177-A1 | TAU IMAGING PROBE | Clino Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012057312-A1 | TAU IMAGING PROBE | クリノ株式会社 (JP) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008494-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | MAOB 2859/4885MAPT 1/4885PDE3B 4382/4885 |
| US-20130324523-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | MAOB 2859/4885MAPT 1/4885PDE3B 4382/4885 |
| US-20160271278-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | MAOB 2859/4885MAPT 1/4885PDE3B 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.